Boston Scientific sees sales increases in 1999
Interventional medical device manufacturer Boston Scientific reported healthy results for fourth quarter and fiscal 1999 (end-December). The Natick, MA, company posted net sales for the quarter of $717 million, flat with sales for the same period in
Interventional medical device manufacturer Boston Scientific reported healthy results for fourth quarter and fiscal 1999 (end-December). The Natick, MA, company posted net sales for the quarter of $717 million, flat with sales for the same period in 1998. Net income was $107 million, up from $71 million the previous year. For the year, the company saw a 27% increase in net sales, from $2.2 billion in 1998 to $2.8 billion in 1999. Net income for the year was $371 million. Excluding charges and credits related to the companys acquisition activity, net income rose 39%, from 1998s $262 million to $364 million.
Boston Scientific attributed its increased income in part to the completion of its acquisition of Schneider Worldwide, a division of Pfizers Medical Technology Group, which the company agreed to purchase in 1998 for $2.1 billion in cash (SCAN 6/24/98). Schneider operates out of Bulach, Switzerland, and manufactures stents and angioplasty devices and accessories. With Schneider under its corporate umbrella, Boston Scientific has gained access to high-growth areas of interventional medicine products, including rapid-exchange catheters and nylon balloon technology.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
